Jazz Agrees To Pay $145M To Settle Xyrem Antitrust Fight
By Rae Ann Varona · April 8, 2025, 11:53 PM EDT
Jazz Pharmaceuticals has agreed to pay $145 million to resolve antitrust litigation accusing it of working with its rival Hikma Pharmaceuticals to stave off generic competitors to Jazz's narcolepsy drug Xyrem,...
To view the full article, register now.